Insights & news

Austria Further Member State to Combat Medicine Shortages

  • 25/10/2019
  • Articles

On 18 October 2019, Austria notified to the European Commission (the “Commission”) a series of proposed measures to tackle medicine shortages (see, attached notification). The notification, based on Directive (EU) 2015/1535 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services, should allow the Commission and other Member States to offer their view on the compatibility of the proposed measures with EU pharmaceutical law and with the rules governing the free movement of goods. Only a few days earlier, the Czech Republic took a similar step (see, Van Bael & Bellis Life Sciences Newsflash, 15 October 2019). Many more Member States have taken action in this area or are contemplating doing so. 

Austria seeks to adopt the following measures to ensure the availability of prescription-only medicines:  

  • Obligation for the marketing authorisation holder to notify immediately any limitations on the distribution of a prescription proprietary medicinal product in Austria.
  • Publication of notified proprietary medicinal products on the website of the Federal Office for Safety in Healthcare (Bundesamt für Sicherheit im Gesundheitswesen).
  • Obligation of notification resting on the Federal Office for Safety in Healthcare if the marketing authorisation holder does not observe its notification obligation or if for other reasons the supply does not adequately cover patient  needs.
  • Introduction of possibility to ban exports to another EEA Member State. 

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 04/06/2020
    • Articles

    Europe - Four-Country Inclusive Vaccine Alliance In Quest for Covid-19 Vaccine

    In a letter to Parliament and a press release (see, attachments), the Dutch Minister for Public Health, Wellbeing and Sports, Hugo de Jonge, revealed on 3 June 2020 an initiative of Italy, France, Germany and The Netherlands to work together to secure a Covid-19 vaccine for “the European Union and other countries”.   According to the Minister, the “Inclusive Vaccine Alliance” (IVA) is in talks with several pharmaceutical companies regarding promising ventures and in the process hopes to establish a European manufacturing base for the vaccine. The IVA’s ultimate goal is to create a medicine that is “accessible, available and affordable”.   Other countries will be given the opportunity to join the IVA which is also in contact with the European Commission.

    Read more
    • 03/06/2020
    • Articles

    European Commission Publishes Roadmap Towards Pharmaceutical Strategy for Europe

    The European Commission (the Commission) published on 2 June 2020 its roadmap towards a Pharmaceutical Strategy for Europe (PSE) which it plans to publish in the fourth quarter of 2020 (see, attachment). The roadmap defines the steps which the Commission will take prior to adopting the PSE and the data which it will assemble to inform its PSE. While the Commission will consult a range of stakeholders, it has already announced a public consultation which will run until 7 July 2020.

    Read more
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *